Navigation Links
ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
Date:9/17/2012

CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.  ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. 

(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D.   "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services.  Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays." 

These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative.  The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.

Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."

About ChanTest – The Ion Channel Expert

ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 

CONTACT: Chris Mathes, +1-732-586-1073

 


'/>"/>
SOURCE ChanTest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest hires Chris Mathes as Chief Commercial Officer
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. QBC Diagnostics Awarded GSA Contract
4. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
5. Northwest Bio Awarded $5.5 Million German Government Grant
6. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
7. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
Breaking Medicine News(10 mins):